Tissue Regenix (GB:TRX) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tissue Regenix’s subsidiary, CellRight Technologies, has extended its distribution agreement with Arthrex, Inc. until 2029, ensuring continued access to its innovative orthobiologics for surgical procedures. This extension highlights a strategic partnership aimed at improving patient outcomes through advanced medical technology. Investors may find this development promising as it strengthens Tissue Regenix’s market position in regenerative medicine.
For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.
